Stockscreener 앱 받기
5.58
3.46%
-0.20
시간 외 거래:
5.62
0.04
+0.72%
전일 마감가:
$5.78
열려 있는:
$5.7
하루 거래량:
72,014
Relative Volume:
5.33
시가총액:
$200.54M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$5.55
$5.7459
1주일 범위
$5.40
$5.90
52주 변동 폭
$5.40
$5.90
Anteris Technologies Global Corp Stock (AVR) Company Profile
AVR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVR
Anteris Technologies Global Corp
|
5.58 | 200.54M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
114.23 | 198.13B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
364.60 | 138.99B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
88.95 | 131.10B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
81.03 | 103.90B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.81 | 44.12B | 6.60B | 4.16B | 490.10M | 6.93 |
Anteris Technologies Global Corp 주식(AVR)의 최신 뉴스
Anteris Technologies’ Bold Shift to U.S. Markets - MSN
Admedus Limited to Relocate Corporate Services Functions to Brisbane; Announces Executive Changes - Marketscreener.com
Admedus Ltd : Admedus's CardioCel® Cleared for Sale in the US - Marketscreener.com
Anteris Technologies Redeems Convertible Notes - TipRanks
Anteris Technologies Announces New Director Appointment - TipRanks
Anteris Technologies Debuts on NASDAQ with IPO - MSN
Anteris Technologies Prepares for Stock Market Expansion - MSN
Anteris Completes Key Animal Study for EFS Submission - Marketscreener.com
Allied Healthcare Group Ltd : Allied reports no calcification from phase II CardioCel patients after 5 years - Marketscreener.com
Anteris Technologies Ltd Provides Data Update on First in Human Study of DurAVR THV Presented At New York Valves 2024 - Marketscreener.com
Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston - Marketscreener.com
Admedus Limited Appoints Maja Mcguire as Company Secretary - Marketscreener.com
Anteris Submits Confidential Draft Registration Statement for Proposed US IPO - Marketscreener.com
Anteris Technologies Ltd Reports Successful Interim Results for the First-In-Human Trial - Marketscreener.com
Admedus Limited Announces Management Changes - Marketscreener.com
Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering - Marketscreener.com
Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study - Marketscreener.com
Anteris Technologies CEO talks A$35 million raise and 2023 milestones - Marketscreener.com
Anteris Technologies closes USD 88.8M US IPO - Medical Buyer
Anteris Technologies Completes $89 Million US IPO; to list CDIs on ASX; Shares Fall 15% - Marketscreener.com
Anteris Technologies Advances with SEC Filing - TipRanks
Anteris Technologies Completes $88.8M NASDAQ IPO for Revolutionary Heart Valve Development - StockTitan
Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering - Business Wire
AVRAnteris Technologies Global Corp. Latest Stock News & Market Updates - StockTitan
Anteris Technologies Expands with U.S. IPO and Innovations - TipRanks
Anteris re-domiciliation finalised: shares trading on ASX and Nasdaq - Proactive Investors UK
Anteris Technologies goes public in U.S. - Minneapolis / St. Paul Business Journal
New Nasdaq Debut! - Jomfruland.net
Anteris Technologies Updates Bylaws to Enhance Governance - TipRanks
Anteris Technologies’ Strategic Move to the US - TipRanks
Anteris Technologies Launches New Equity Incentive Plan - TipRanks
Anteris Technologies Lists on Nasdaq Following IPO - TipRanks
Anteris Technologies lists on Nasdaq with IPO set at US$6.00 per share - Proactive Investors USA
Australian medtech Anteris stock slides 8% after $89M IPO - MSN
BTC Speciality Health Pty Ltd agreed to acquire Hospital Infusion Business from Admedus Limited. - Marketscreener.com
Admedus Limited announced that it has received AUD 6 million in funding - Marketscreener.com
U.S. IPO Weekly Recap: ServiceTitan Shines In 3 IPO Week - Seeking Alpha
Anteris Technologies Launches U.S. IPO on Nasdaq - TipRanks
Admedus : announces Placement and Rights Issue - Marketscreener.com
Anteris Technologies Ltd announced that it expects to receive funding from Mercer Street Capital Partners, LLC - Marketscreener.com
Anteris Technologies prices IPO at $6 per share (Pending:AVR) - Seeking Alpha
Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering - Yahoo Finance
Anteris Technologies Prices $88.8M Nasdaq IPO for Revolutionary Heart Valve Development - StockTitan
Allied Healthcare Group Ltd. Announces Board Changes - Marketscreener.com
Anteris Technologies Ltd Announces Fda Approves Early Feasibility Study for DurAVR THV System - Marketscreener.com
Anteris Technologies Secures US Patent for Transcatheter Heart Valve; Shares Rise 4% - Marketscreener.com
Anteris Technologies Ltd Provides Update on First In Human DurAVR THV Study - Marketscreener.com
Anteris Technologies Announces Research Partnership with Yale University and Ycrg - Marketscreener.com
Anteris Technologies Ltd Overnight Presents 30-Day Clinical Data for Full Cohort of 13 Patients Implanted with DurAVR THV During Its First-In-Human Trial - Marketscreener.com
Anteris Technologies Ltd Presents "DurAVR transcatheter aortic valve first-in- human study: impact of novel leaflet design" at the annual PCR London Valves 2022, 27-29 November 2022 - Marketscreener.com
Anteris Technologies Ltd Announces Formal Results of A Comparative Study to Investigate Aortic Flow Physiology by Cardiac MRI in Five Patients Who Received A DurAVR Transcatheter Aortic Valve (First- In-Human) - Marketscreener.com
Anteris Technologies Global Corp (AVR) 재무 분석
Anteris Technologies Global Corp (AVR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.54%
자본화:
|
볼륨(24시간):